Background Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-…

… of kidneys via commercial airlines represents a significant and indirect impact of COVID-19
on the kidney transplantation community. Patients, providers, transplant centers, and OPOs …

… transplantation as compared with non-transplanted counterparts.111 The updated statement
now emphasises that ‘transplantation … undergo pre-emptive transplantation, although this …

… ) and grading of recommendations considered the total body … can be used, with transplantation
having the most favourable … patients who underwent transplantation versus those who did …

… and transplant candidates. … transplantation, but their role in optimizing CMV prevention
and treatment efforts has yet to be demonstrated. Specific issues related to pediatric transplant …

… There are issues with using accepted primary outcomes of liver transplantation trials in the
context of MP trials, and no ideal endpoint could be defined by the working group. The setup …

… Although such refusal is consistent with duties to prevent harm to the patient, given the
clinical, financial and legal risks associated with travel for commercial transplantation, in many …

… Only one of the commercial CAR T-cell manufacturers – Novartis – currently requires …
The other commercial manufacturers will collect fresh apheresis product packed in their …

… by not informing issues such as access to transplantation, and impact of transplant center
choice … is not only used for patient education and oversight, but also for commercial purposes. …

… on its impact on hepatologists, liver transplant providers, patients with liver disease, and liver
transplant recipients. We provide clinicians with guidance for how to minimize the impact of …